Oculis Holding AG OCS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $12.61
- Day Range
- $12.11–12.76
- 52-Week Range
- $10.52–34.48
- Bid/Ask
- $12.10 / $14.50
- Shares Outstanding
- 60.39M
- Market Cap
- $736.13M
- Volume/Avg
- 304,143 / 730,076
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 60
- Website
- https://www.oculis.com
Valuation
|
Metric
|
OCS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.59 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OCS
|
|---|---|
Quick Ratio | 5.10 |
Current Ratio | 5.18 |
Interest Coverage | −126.18 |
Quick Ratio
OCS
Profitability
|
Metric
|
OCS
|
|---|---|
Return on Assets (Normalized) | −32.85% |
Return on Equity (Normalized) | −48.60% |
Return on Invested Capital (Normalized) | −41.03% |
Return on Assets
OCS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|K<F^WvG | LOCK|^!#& | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|BNNV%S> | LOCK|N#Kp | $71B | |||
| argenx SE ADR
ARGX
| LOCK|HGtn$<K | LOCK|<KK | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|CW<YMs | LOCK|%%> | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|l!N^WD | LOCK|j&Zz | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|n#@QL&r | LOCK|mwqXk | $26B | |||
| Moderna Inc
MRNA
| LOCK|T@cSXk | LOCK|vjQ | $25B | |||
| Incyte Corp
INCY
| LOCK|GY%<R!% | LOCK|>G | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!x>&>Z? | LOCK|&t | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?dnf#kw | LOCK|zps | $16B |
United States